Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cubist gets option to acquire pain management biotech Adynxx; option not exercised

Executive Summary

In exchange for a $20mm up-front fee, acute care product company Cubist Pharmaceuticals Inc. has obtained the exclusive option to buy closely held Adynxx Inc. (pain management) following receipt of the Phase II data on Adynxx’s lead pain drug AYX1 (the proof-of-concept trial enrolled its first patient concurrent with this announcement). Should Cubist exercise the option, it would pay $40mm plus development, regulatory, and sales earn-outs.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Earnout
    • Intra-Biotech Deal
    • Payment Includes Cash

Related Companies